Health Catalyst (NASDAQ:HCAT) PT Lowered to $7.00

Health Catalyst (NASDAQ:HCAT) had its target price cut by Stephens from $8.00 to $7.00 in a research report sent to investors on Thursday morning, Benzinga reports. They currently have an equal weight rating on the stock.

Several other analysts also recently issued reports on HCAT. Piper Sandler decreased their price target on Health Catalyst from $15.00 to $14.00 and set an overweight rating for the company in a research note on Thursday, June 6th. Canaccord Genuity Group restated a buy rating and set a $11.00 target price on shares of Health Catalyst in a research note on Tuesday, May 21st. Cantor Fitzgerald restated an overweight rating and set a $16.00 target price on shares of Health Catalyst in a research note on Wednesday, April 10th. KeyCorp restated a sector weight rating on shares of Health Catalyst in a research note on Wednesday, April 10th. Finally, Evercore ISI cut their price target on Health Catalyst from $9.00 to $8.00 and set an outperform rating for the company in a report on Tuesday, July 9th. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of Moderate Buy and an average target price of $11.50.

Health Catalyst Trading Down 11.9 %

NASDAQ HCAT traded down $0.90 on Thursday, reaching $6.65. The stock had a trading volume of 741,871 shares, compared to its average volume of 601,386. The business has a 50 day moving average price of $6.62 and a 200 day moving average price of $7.31. Health Catalyst has a 1 year low of $5.42 and a 1 year high of $13.20. The company has a market capitalization of $392.58 million, a price-to-earnings ratio of -3.59 and a beta of 1.32.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings results on Wednesday, August 7th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.04. The company had revenue of $75.90 million during the quarter, compared to the consensus estimate of $74.96 million. Health Catalyst had a negative return on equity of 11.86% and a negative net margin of 35.56%. The firm’s revenue was up 3.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.21) EPS. On average, analysts anticipate that Health Catalyst will post -0.4 earnings per share for the current fiscal year.

Insider Activity at Health Catalyst

In related news, COO Daniel Lesueur sold 5,209 shares of the firm’s stock in a transaction on Monday, August 5th. The stock was sold at an average price of $6.19, for a total transaction of $32,243.71. Following the completion of the sale, the chief operating officer now directly owns 150,006 shares of the company’s stock, valued at approximately $928,537.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 13,773 shares of company stock valued at $87,133 in the last three months. Corporate insiders own 2.70% of the company’s stock.

Institutional Investors Weigh In On Health Catalyst

Hedge funds and other institutional investors have recently bought and sold shares of the business. Valmark Advisers Inc. acquired a new stake in Health Catalyst during the 4th quarter valued at $1,204,000. Primecap Management Co. CA increased its holdings in Health Catalyst by 26.7% during the 4th quarter. Primecap Management Co. CA now owns 1,419,577 shares of the company’s stock valued at $13,145,000 after purchasing an additional 299,139 shares in the last quarter. Kennedy Capital Management LLC bought a new position in Health Catalyst in the 1st quarter valued at $8,780,000. ClariVest Asset Management LLC boosted its position in Health Catalyst by 303.9% in the 1st quarter. ClariVest Asset Management LLC now owns 282,325 shares of the company’s stock valued at $2,126,000 after buying an additional 212,425 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its position in Health Catalyst by 38.3% in the 1st quarter. Acadian Asset Management LLC now owns 724,560 shares of the company’s stock valued at $5,453,000 after buying an additional 200,494 shares during the last quarter. 85.00% of the stock is owned by institutional investors and hedge funds.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.